Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Mitsubishi UFJ Trust & Banking Corp

Key Points

• Mitsubishi UFJ Trust & Banking Corp reduced its stake in Jazz Pharmaceuticals by 19.1% in Q4, selling 9,703 shares and now holds 41,166 shares worth about $6.99 million (0.07% of the company).
• Several large institutions increased positions—Goldman Sachs boosted its stake 147.7% to 351,609 shares and Royal Bank of Canada nearly doubled to 67,614 shares—contributing to institutions and hedge funds owning roughly 89.14% of Jazz.
• Insiders sold a total of 74,015 shares (≈$14.18M) in the last quarter, even as analysts remain largely positive with a consensus "Moderate Buy" rating and an average price target of $216.87.

Mitsubishi UFJ Trust & Banking Corp lessened its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 19.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 41,166 shares of the specialty pharmaceutical company's stock after selling 9,703 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned 0.07% of Jazz Pharmaceuticals worth $6,999,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JAZZ. Royal Bank of Canada increased its holdings in shares of Jazz Pharmaceuticals by 96.5% in the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company's stock valued at $8,394,000 after purchasing an additional 33,210 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 147.7% during the first quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company's stock worth $43,652,000 after purchasing an additional 209,667 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Jazz Pharmaceuticals by 4.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company's stock worth $24,479,000 after purchasing an additional 7,954 shares during the period. Focus Partners Wealth grew its position in Jazz Pharmaceuticals by 3.4% in the 1st quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company's stock valued at $574,000 after buying an additional 154 shares during the last quarter. Finally, Geneos Wealth Management Inc. grew its position in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after buying an additional 137 shares during the last quarter. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In other news, CAO Patricia Carr sold 1,287 shares of the business's stock in a transaction on Monday, March 9th. The stock was sold at an average price of $182.94, for a total value of $235,443.78. Following the completion of the transaction, the chief accounting officer directly owned 6,512 shares of the company's stock, valued at $1,191,305.28. The trade was a 16.50% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Bruce C. Cozadd sold 6,000 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares in the company, valued at $73,281,921. This represents a 1.54% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 74,015 shares of company stock worth $14,180,486 in the last quarter. Insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of analyst reports. Bank of America upped their price objective on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research report on Wednesday, February 25th. Piper Sandler boosted their price target on shares of Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an "overweight" rating in a research note on Thursday, March 19th. Wells Fargo & Company increased their price target on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a report on Wednesday, February 25th. Royal Bank Of Canada raised their price objective on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the company an "outperform" rating in a research report on Wednesday, February 25th. Finally, Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an "overweight" rating in a report on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $216.87.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock opened at $202.72 on Friday. The company has a market cap of $12.72 billion, a P/E ratio of -33.96, a price-to-earnings-growth ratio of 0.35 and a beta of 0.27. Jazz Pharmaceuticals PLC has a one year low of $97.50 and a one year high of $207.48. The business has a fifty day moving average of $189.65 and a two-hundred day moving average of $170.85. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share for the quarter, topping the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The company had revenue of $1.20 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the prior year, the business posted $6.51 earnings per share. The firm's revenue for the quarter was up 8.1% compared to the same quarter last year. As a group, analysts predict that Jazz Pharmaceuticals PLC will post 20.51 earnings per share for the current fiscal year.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.